NLRP3 and Alzheimer disease: NLRP3 inhibitors are novel senotherapeutic agents that delay EC senescence and microbial translocation, suggesting beneficial effects in both AD and chronic inflammation (Yi, 2017; Yin et al., 2017; McAllister et al., 2018; Qi et al., 2018).